4.49

1.13% +0.05

After Hours: 4.49

G1 Therapeutics Inc (GTHX)

Overview News Price History Option Chain Financials Why GTHX Down? Discussions Forecast

G1 Therapeutics Inc stock is currently priced at $4.49, with a 24-hour trading volume of 574.43K. It has seen a +1.13% increased in the last 24 hours and a -4.87% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $4.36 pivot point. If it approaches the $4.59 resistance level, significant changes may occur.

Previous Close:

$4.44

Open:

$4.56

24h Volume:

574.43K

Market Cap:

$234.85M

Revenue:

$82.51M

Net Income/Loss:

$-47.97M

P/E Ratio:

-2.6568

EPS:

-1.69

Net Cash Flow:

$-38.34M

1W Performance:

+12.53%

1M Performance:

-4.87%

6M Performance:

+168.86%

1Y Performance:

+48.68%

1D Range:

$4.48

$4.70

52W Range:

$1.08

$5.00

G1 Therapeutics Inc Stock (GTHX) Company Profile

Name

G1 Therapeutics Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

919-213-9835

Address

79 T.W. Alexander Drive, Suite 100 4501 Research Commons, Research Triangle Park, NC

Employee

Twitter

@G1Therapeutics

Next Earnings Date

2024-05-01

Latest SEC Filings

GTHX's Discussions on Twitter

G1 Therapeutics Inc Stock (GTHX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-23	Upgrade	JP Morgan	Underweight → Neutral
Jan-03-23	Reiterated	Needham	Buy
Nov-04-21	Downgrade	JP Morgan	Neutral → Underweight
Oct-15-21	Resumed	BTIG Research	Buy
Sep-30-21	Downgrade	JP Morgan	Overweight → Neutral
Nov-17-20	Downgrade	Raymond James	Strong Buy → Outperform
Jun-26-20	Initiated	ROTH Capital	Buy
Jan-21-20	Reiterated	H.C. Wainwright	Buy
Aug-08-19	Upgrade	JP Morgan	Neutral → Overweight
Feb-07-19	Initiated	B. Riley FBR	Buy
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Dec-20-18	Initiated	Raymond James	Strong Buy
Nov-08-18	Reiterated	Needham	Buy
Sep-10-18	Resumed	BTIG Research	Buy
May-29-18	Initiated	H.C. Wainwright	Buy
May-18-18	Reiterated	Needham	Buy

View All

G1 Therapeutics Inc Stock (GTHX) Latest News

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Evaluating G1 Therapeutics: Insights From 5 Financial Analysts

Benzinga

G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research

G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights

GlobeNewswire Inc.

G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib

GlobeNewswire Inc.

G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024

GlobeNewswire Inc.

G1 Therapeutics Inc Stock (GTHX) Financials Data

G1 Therapeutics Inc (GTHX) Revenue 2024

GTHX reported a revenue (TTM) of $82.51 million for the quarter ending December 31, 2023, a +60.84% rise year-over-year.

G1 Therapeutics Inc (GTHX) Net Income 2024

GTHX net income (TTM) was -$47.97 million for the quarter ending December 31, 2023, a +67.49% increase year-over-year.

G1 Therapeutics Inc (GTHX) Cash Flow 2024

GTHX recorded a free cash flow (TTM) of -$38.34 million for the quarter ending December 31, 2023, a +70.31% increase year-over-year.

G1 Therapeutics Inc (GTHX) Earnings per Share 2024

GTHX earnings per share (TTM) was -$0.95 for the quarter ending December 31, 2023, a +71.81% growth year-over-year.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.